Enrollment in clinical trials is key in advancing new treatments for patients with cancer. Poor accrual can result in trials that fail to complete or generate less timely research findings for patients in need of better therapies. The outbreak of coronavirus disease 2019 (COVID-19) has caused severe disruptions in care for many patients—especially patients with cancer, who are more susceptible to infections because of underlying malignant neoplasms or therapy—in an effort to reduce patient and staff exposure and to preserve resources. Given systemwide changes, some institutions in areas with high rates of COVID-19 have stopped all enrollment in interventional trials, while others have made minor changes. An important question is how the COVID-19 pandemic is associated with national enrollment in cancer clinical trials.
Sign in to take quiz and track your certificates
JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 Credit(s)™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC
CME Disclosure Statement: Unless noted, all individuals in control of content reported no relevant financial relationships. If applicable, all relevant financial relationships have been mitigated.
Accepted for Publication: May 4, 2020.
Published: June 1, 2020. doi:10.1001/jamanetworkopen.2020.10651
Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2020 Unger JM et al. JAMA Network Open.
Corresponding Author: Joseph M. Unger, PhD, SWOG Statistics and Data Management Center, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, M3-C102, PO Box 19024, Seattle, WA 98109-1024 (firstname.lastname@example.org).
Author Contributions: Dr Unger had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Unger, Hershman.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: All authors.
Critical revision of the manuscript for important intellectual content: Unger, Blanke, Hershman.
Statistical analysis: Unger.
Obtained funding: Unger, Blanke.
Administrative, technical, or material support: Blanke, LeBlanc.
Supervision: Unger, Blanke.
Conflict of Interest Disclosures: Dr LeBlanc reported receiving grants from the National Institutes of Health outside the submitted work. No other disclosures were reported.
Funding/Support: Research reported in this article was supported in part by grant 5UG1CA189974 from the Division of Cancer Prevention, National Cancer Institute, National Institutes of Health (Drs Blanke and Hershman); grants U10CA180888 and U10CA180819 from the National Cancer Institute, National Institutes of Health (Drs Blanke and Leblanc, respectively); and in part by The Hope Foundation for Cancer Research in support of infrastructure, data analysis, and trial design within the SWOG Cancer Research Network, at the SWOG Statistics and Data management Center (Dr Unger).
Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Additional Contributions: We wish to recognize all the SWOG researchers and investigators on the front lines of patient care. In addition, the authors wish to thank SWOG staff members Cathy Rankin, MS, for development of coronavirus disease 2019–related data on SWOG trials and Dana Sparks, MAT, for overseeing SWOG protocol changes and memos related to coronavirus disease 2019. They were compensated for their time.
You currently have no searches saved.
You currently have no courses saved.